# Trade Mark Journal No.2026/011 13 March 2026

## WO0000001888670 (40,42)

Office of origin: Benelux Office for Intellectual Property (BOIP)

Date of International Registration:21 October 2025
Date of designation in the UK: 21 October 2025

Class 40
  Custom manufacturing of cell culture and cell therapy and gene edited cell therapy apparatus and equipment for others; custom manufacture of medicines; custom manufacture of biopharmaceuticals, namely, therapeutic cells, laboratory-modified cells, and gene edited cells to prevent or treat conditions or diseases that can be transferred into the body, for others; information, advice and consultancy in relation to all the aforesaid.
Class 42
  Platform-as-a-service [PaaS] in the field of cell therapy, and cell therapy development; providing temporary use of a a web-based platform that offers tools, technologies, processes and data analysis capabilities for researchers and scientists to streamline the development and characterization of cell lines; providing temporary use of a technological platform for the manufacturing of cell-based therapies, including technology, processes, and data analytics capabilities for process optimization and quality control; platform-as-a-service [PaaS] for monitoring patient health; laboratory research in the field of biotechnology; scientific research, design and technological development services in biotechnology, the pharmaceutical and medical industry; scientific research, design and development of scientific cell culture, cell therapy or gene edited cell therapy equipment and apparatus; scientific research, design and development of cell culture, cell therapy or gene edited cell therapy manufacturing equipment, manufacturing systems and manufacturing processes for others; scientific consultation services in the field of biotechnology, specifically in relation to cell culture, cell therapy, or gene edited cell therapy manufacturing; providing information with respect to scientific research in the field of stem cells, cell therapy and edited cell gene therapy; initial set-up, configuration, and calibration, of scientific apparatus, machines and equipment used for cell culture, cell therapy and edited cell gene therapy; industrial biotechnology statistical analysis to extract insights from cell line development experiments and data; research and development in the field of cells, therapeutic cells, cell therapies, cellular therapies and gene edited cell therapies; culturing of cells for scientific research purposes.

Celyntra Therapeutics SA

Representative: NLO Shieldmark B.V., New Babylon City Offices Anna van Buerenplein 21 A, NL-2595 DA Den Haag, NETHERLANDS